NASDAQ:IDXX - IDEXX Laboratories Stock Price, Forecast & News

IDEXX Laboratories trades on the NASDAQ under the ticker symbol "IDXX."

IDEXX Laboratories declared that its Board of Directors has authorized a share buyback plan on Wednesday, February 12th 2020, which permits the company to buyback 5,000,000 shares, according to EventVestor. This buyback authorization permits the company to reacquire shares of its stock through open market purchases. Stock buyback plans are usually an indication that the company's leadership believes its stock is undervalued.

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings data on Friday, January, 31st. The company reported $1.04 earnings per share for the quarter, topping analysts' consensus estimates of $0.91 by $0.13. The business earned $605.50 million during the quarter, compared to analyst estimates of $600.60 million. The business's revenue was up 10.2% compared to the same quarter last year. During the same period in the prior year, the company earned $0.98 EPS. View IDEXX Laboratories' Earnings History.

IDEXX Laboratories is scheduled to release their next quarterly earnings announcement on Wednesday, May 6th 2020. View Earnings Estimates for IDEXX Laboratories.

IDEXX Laboratories issued an update on its FY20 earnings guidance on Friday, January, 31st. The company provided earnings per share (EPS) guidance of $5.42-5.58 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.41. The company issued revenue guidance of $2.62-2.66 billion, compared to the consensus revenue estimate of $2.63 billion.

6 brokers have issued 12-month price objectives for IDEXX Laboratories' stock. Their forecasts range from $277.00 to $310.00. On average, they anticipate IDEXX Laboratories' stock price to reach $293.33 in the next year. This suggests a possible upside of 1.6% from the stock's current price. View Analyst Price Targets for IDEXX Laboratories.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for IDEXX Laboratories.

News coverage about IDXX stock has been trending neutral recently, InfoTrie reports. The research group ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. IDEXX Laboratories earned a media sentiment score of 0.2 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View News Stories for IDEXX Laboratories.

IDEXX Laboratories saw a decline in short interest in the month of January. As of January 31st, there was short interest totalling 1,210,000 shares, a decline of 6.9% from the January 15th total of 1,300,000 shares. Based on an average trading volume of 507,000 shares, the short-interest ratio is currently 2.4 days. Approximately 1.4% of the company's shares are sold short. View IDEXX Laboratories' Current Options Chain.

Some companies that are related to IDEXX Laboratories include Abbott Laboratories (ABT), ABIOMED (ABMD), CONMED (CNMD), ProShares UltraShort DJ-UBS Commodity (CMD), Synthorx (THOR), AtriCure (ATRC), AngioDynamics (ANGO), Alphatec (ATEC), Accuray (ARAY), Fc Global Realty (FCRE), Navidea Biopharmaceuticals (NAVB), Baxter International (BAX), Becton Dickinson and (BDX), Boston Scientific (BSX) and Cardiovascular Systems (CSII).

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Paypal (PYPL), Alibaba Group (BABA), Netflix (NFLX), Adobe (ADBE), Mastercard (MA), Intuitive Surgical (ISRG), Home Depot (HD), Micron Technology (MU) and salesforce.com (CRM).

IDEXX Laboratories' stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (4.40%), Blair William & Co. IL (1.80%), Principal Financial Group Inc. (1.39%), Franklin Resources Inc. (1.19%), Bank of America Corp DE (0.89%) and Bank of New York Mellon Corp (0.83%). Company insiders that own IDEXX Laboratories stock include Brian P Mckeon, Bruce L Claflin, Daniel M Junius, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, Lawrence D Kingsley, M Anne Szostak, Michael Lane, Rebecca M Henderson, Sophie V Vandebroek and William T End. View Institutional Ownership Trends for IDEXX Laboratories.

IDXX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Marshall Wace North America L.P., Skandinaviska Enskilda Banken AB publ , Massachusetts Financial Services Co. MA, MERIAN GLOBAL INVESTORS UK Ltd, MERIAN GLOBAL INVESTORS UK Ltd, Los Angeles Capital Management & Equity Research Inc. and First Trust Advisors LP. Company insiders that have sold IDEXX Laboratories company stock in the last year include Brian P Mckeon, Giovani Twigge, Jacqueline Studer, Jay Mazelsky, Jonathan W Ayers, M Anne Szostak, Michael Lane, Rebecca M Henderson and Sophie V Vandebroek. View Insider Buying and Selling for IDEXX Laboratories.

IDXX stock was acquired by a variety of institutional investors in the last quarter, including KBC Group NV, Robeco Institutional Asset Management B.V., Beacon Investment Advisory Services Inc., State Street Corp, Credit Suisse AG, Bank of Montreal Can, Great Diamond Partners LLC and Duality Advisers LP. Company insiders that have bought IDEXX Laboratories stock in the last two years include Bruce L Claflin and Lawrence D Kingsley. View Insider Buying and Selling for IDEXX Laboratories.

Shares of IDXX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of IDXX stock can currently be purchased for approximately $288.78.